CURE biotech ETF receives investment grade rating
ETF Securities has received an “investment grade” rating for its CURE ETF from ratings firm Lonsec.
CURE began trading on the Australian Securities Exchange (ASX) in November last year and replicated the S&P Biotechnology Select Industry Index, which achieved annual growth of almost 22 per cent over the last five years.
The Lonsec product review had described the fund as: “the only ETF of its kind to provide a pure US Biotechnology thematic exposure on the ASX”. Lonsec believes the Fund provided investors with an efficient and relatively transparent means to gain an economic interest to the biotechnology market in the US.
Kris Walesby, head of ETF Securities Australia, said the Lonsec rating would provide local investors with increased confidence they had broader options than the Australian market.
“When it comes to a large universe of healthcare biotech stocks, the US is where you need to look for the best chance of ground-breaking developments and consequent investment returns,” Walesby said.
AUTHOR
Chris Dastoor
Recommended for you
Trustee and fund administration platform MSC Group has promoted Shelley Brown as its chief operations officer, having successfully completed the integration of the Certane Corporate Trust business.
Australian Unity’s group managing director and chief executive has announced his plans to retire at the end of the year after two decades leading the company.
TAL has appointed a senior manager for investment strategy and portfolio management who joins from a lead role at AIA.
Global wealth management platform FNZ has appointed a new group head of APAC, while boutique investment manager TWC Invest welcomes a chief technology officer.
